Page Menu

Translational Research - Key Publications Over the Last Five Years

1. Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs 2011 Dec; 29: (6) 1381-1389 PMID: 20644979. PMCID: PMC4612514. IF: 2.919

2. Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res 2011 Mar; 17: (5) 1140-1146 PMID: 21233404. PMCID: PMC3049960. IF: 8.722

3. Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clin Cancer Res 2011 Dec; 17: (24) 7743-7753 PMID: 22028494. PMCID: PMC4521635. IF: 8.722

4. Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012 Jan; 11: (1) 174-182 PMID: 22084170. PMCID: PMC4545500. IF: 5.683

5. Gray J, Cubitt CL, Zhang S, Chiappori A. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther 2012 Jun; 13: (8) 614-622 PMID: 22441819. PMCID: PMC3408970. IF: 3.072

6. Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One 2013 Sep; 8: (3) e57523- PMID: 23520471.PMCID: PMC3592874. IF: 3.234

7. Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ. Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis 2013 Aug; 4: e566- PMID: 23538447. PMCID: PMC3613821.IF: 5.014

8. Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J Med Chem 2013 May; 56: (10) 3768-3782 PMID: 23600925. PMCID: PMC3714109. IF: 5.447

9. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology 2013 Mar; 2: (3) e23428- PMID: 23802083. PMCID: PMC3661168. IF: 6.266  

10. Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biol Ther 2013 Oct; 14: (10) 932-936 PMID: 23917345. PMCID: PMC3926890. IF: 3.072  

11. Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, Antonia S. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther 2013 Sep; 14: (9) 860-868 PMID: 23917542. PMCID: PMC3909555. IF: 3.072

12. Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR. Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma 2013 Nov; 2013: 365723- PMID: 24282374. PMCID: PMC3824404.

13. Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res 2014 Jan; 74: (1) 56-67 PMID: 24310398. PMCID: PMC3915502. IF: 9.329  

14. Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res 2014 Mar; 20: (6) 1644-1655 PMID: 24429877. PMCID: PMC4051132. IF: 8.722

15. Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process? J Geriatr Oncol 2014 Jan; 5: (1) 40-48 PMID: 24484717. PMCID: PMC4527303. IF: 1.859

16. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol 2014 Aug; 27: 62-73 PMID: 24631834. PMCID: PMC4108511. IF: 9.330

17. Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest 2014 Jun; 124: (6) 2585-2598 PMID: 24812669. PMCID: PMC4038575. IF: 13.215

18. Kurtyka CA, Chen L, Cress WD. E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One 2014 ; 9: (5) e96357- PMID: 24831239. PMCID: PMC4022639. IF: 3.234

19. Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget2014 Sep; 5: (18) 8136-8146 PMID: 25327557. PMCID: PMC4226672. IF: 6.359